P725: Predictive factors for biologic therapy initiation after ileal pouch-anal anastomosisECCO'24Year: 2024
Authors: Fischman, M.(1)*;Godny, L.(2,3);Friedeberg, A.(2,3);Barkan, R.(2,3);White, I.(3,4);Wasserberg, N.(3,4);Dotan, I.(2,3);Ollech, J.E.(2,3);
(1)Hebrew University of Jerusalem, Department of Military Medicine, Jerusalem, Israel;(2)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(3)Tel Aviv University, Faculty of Medicine, Tel Aviv, Israel;(4)Rabin Medical Center, Division of Surgery, Petah Tikva, Israel;
P726: A phase 2 study investigating the efficacy and safety of dupilumab versus placebo in adults with moderately to severely active ulcerative colitis with an eosinophilic phenotypeECCO'24Year: 2024
Authors: Gottlieb, E.(1)*;Binion, D.(2);Feagan, B.(3);Laws, E.(4);Nivens, C.(5);Maloney, J.(5);Abdulai, R.(4);Radin, A.(5);Glotfelty, L.(4);
(1)Sanofi, Sanofi, Stockholm, Sweden;(2)University of Pittsburgh Medical Center, Division of Gastroenterology- Hepatology and Nutrition, Pittsburgh- PA, United States;(3)Alimentiv Inc., Alimentiv Inc., London- ON, Canada;(4)Sanofi, Sanofi, Bridgewater- NJ, United States;(5)Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc., Tarrytown- NY, United States;
P727: Clinical efficacy of apheresis in Ulcerative Colitis. The experience of four tertiary centers.ECCO'24Year: 2024
Authors: Papathanasiou, E.(1)*;Markopoulos, P.(2);Tzouvala, M.(3);Ioannou, A.(1);Tsironi, E.(2);Zacharopoulou, E.(3);Tzakri, M.(1);Pantelakis, E.(1);Leonidakis, G.(1);Bamias, G.(4);Michopoulos, S.(1);Zampeli, E.(1);
(1)@D@Alexandra@D@ General Hospital, Department of Gastroenterology, Athens, Greece;(2)Metaxa Memorial General Hospital, Department of Gastroenterology, Athens, Greece;(3)General Hospital Nikaias-Piraeus @E@Agios Panteleimon@E@-General Hospital Dytikis Attikis @D@Agia Varvara@D@, Department of Gastroenterology, Athens, Greece;(4)Sotiria Hospital- Medical School- National and Kapodistrian University of Athens, GI-Unit- 3rd Academic Department of Internal Medicine, Athens, Greece;
P731: Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A single-center experienceECCO'24Year: 2024
Authors: SinaDr., M.(1)*;Pemaj, X.(1);Djegsi, A.(1);Telaku, S.(2);Prifti, S.(1);
(1)University Hospital Center Mother Theresa, Internal Medicine/ Gastroenterology, Tirana, Albania;(2)UBT, Internal Medicine/ Gastroenterology, Pristina, Kosovo;
P732: Lack of concordance between patient-reported, physician-reported and objective criteria-based identification of suboptimal control in IBD patients: IBD PODCAST study resultsECCO'24Year: 2024
Authors: D@E@Amico, F.(1)*;Gomollón, F.(2);Bamias, G.(3);Magro, F.(4);Heatta-Speicher, T.(5);Michelena, N.(6);Leitner, C.(7);Dignass, A.(8);
(1)IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Gastroenterology and Endoscopy, Milan, Italy;(2)Hospital Clínico Universitario “Lozano Blesa”, Facultad de Medicina, Zaragoza, Spain;(3)Sotiria Hospital- National & Kapodistrian University of Athens, GI-Unit- 3rd Academic Dpt. Of Internal Medicine, Athens, Greece;(4)Faculdade de Medicina da Universidade do Porto, CINTESIS@RISE Departament, Porto, Portugal;(5)AbbVie AS, Immunology, Oslo, Norway;(6)AbbVie Spain- SLU, Immunology, Madrid, Spain;(7)AbbVie Switzerland, Immunology, Cham, Switzerland;(8)Agaplesion Markus Hospital- Goethe University, Department of Medicine I, Frankfurt am Main, Germany;on behalf of the IBD-Podcast study group
P733: Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases treated with intensified doses: the REMSWITCH-LT studyECCO'24Year: 2024
Authors: Buisson, A.(1)*;Nachury, M.(2);Bazoge, M.(3);Yzet, C.(4);Wils, P.(2);Dodel, M.(1);Coban, D.(1);Pereira, B.(1);Fumery, M.(4);
(1)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;(2)CHRU Lille, IBD Unit, Lille, France;(3)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrabd, France;(4)CHU Amiens, IBD Unit, Amiens, France;
P734: Super-responders in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD studyECCO'24Year: 2024
Authors: Schreiber, S.W.(1)*;Sands, B.E.(2);Hanauer, S.B.(3);Danese, S.(4);Loftus Jr, E.V.(5);Jeong, A.L.(6);Kim, D.H.(6);Lee, Y.N.(6);Colombel, J.F.(2);
(1)University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany;(2)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(3)Northwestern University- Feinberg School of Medicine, Division of Gastroenterology and Hepatology- Department of Medicine, Chicago, United States;(4)IRCCS San Raffaele Hospital and Vita-Salute University, Department of Gastroenterology, Milan, Italy;(5)Mayo Clinic College of Medicine and Science, Division of Gastroenterology and Hepatology, Rochester, United States;(6)Celltrion Healthcare Co.- Ltd, Not applicable, Incheon, Korea- Republic Of;
P735: JAK inhibitors and S1P receptor modulators for the treatment of antibiotic refractory chronic pouchitis: an ECCO CONFER Multicentre Case SeriesECCO'24Year: 2024
Authors: Testa, G.(1)*;Ribaldone, D.G.(1);Verstockt, B.(2,3);Molnar, T.(4);Savarino, E.(5);Schmidt, C.(6,7);Vieujean, S.(8);Teich, N.(9);Meianu, C.(10,11);Juillerat, P.(12,13);Grellier, N.(14);Lobaton, T.(15,16);
(1)University of Turin, Department of Medical Sciences- Division of Gastroenterology, Turin, Italy;(2)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)KU Leuven, Department of Chronic Diseases and Metabolism, Leuven, Belgium;(4)University of Szeged, University of Szeged, Szeged, Hungary;(5)University of Padua, Department of Surgery Oncology and Gastroenterology DiSCOG - Division of Gastroenterology, Padua, Italy;(6)Hospital Fulda, Medical Clinic II, Fulda, Germany;(7)Friedrich Schiller University, Medical Faculty, Jena, Germany;(8)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(9)Gastroenterology Practice, Gastroenterology Practice, Leipzig, Germany;(10)Carol Davila University of Medicine and Pharmacy, Faculty of Medicine, Bucharest, Romania;(11)Fundeni Clinical Institute, Gastroenterology Department, Bucharest, Romania;(12)Bern University Hospital - Clinic for Visceral Surgery and Medicine, Department of Gastroenterology, Bern, Switzerland;(13)Gastro-enterologie Beaulieu SA, Crohn and Colitis Center, Lausanne, Switzerland;(14)University Hospital of Poitiers, Hepato-Gastroenterology Department, Poitiers, France;(15)Ghent University, Department of Internal Medicine and Pediatrics-, Ghent, Belgium;(16)University Hospital Ghent, Department of Gastroenterology, Ghent, Belgium;
P738: Response to etrasimod treatment in ulcerative colitis is associated with a reduction of circulating B and pro-inflammatory T cells: a single-cell-based post-hoc sub-analysis of the ELEVATE UC 52 trialECCO'24Year: 2024
Authors: Weidinger, C.(1)*;Milek, M.(2);Hecker, J.(1);Haag, L.M.(1);Freise, I.(1);Obermayer, B.(2);Beule, D.(2);Ryan, R.D.(3);Crosby, C.(3);Siegmund, B.(1);
(1)Charité – Universitätsmedizin Berlin- corporate member of Freie Universität Berlin and Humboldt -Universität zu Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(2)Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Core Unit Bioinformatics, Berlin, Germany;(3)Pfizer Inc., Pfizer Inc., La Jolla- CA, United States;
P739: Translating Pharmacokinetic and Efficacy Outcomes of NLRX1 Agonist NX-13: Contrasting a Pig Model and a Human Phase 1b Clinical Trial in Ulcerative ColitisECCO'24Year: 2024
Authors: Siegmund, B.(1)*;Verstockt, B.(2);Dubinsky, M.(3);Mosig, R.(4);Cataldi, F.(5);Danese, S.(6);Yarur, A.(7);
(1)Charité - Universitätsmedizin Berlin- corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Division of Gastroenterology, Berlin, Germany;(2)University Hospitals Leuven- KU Leuven-, Department of Gastroenterology and Hepatology- Department of Chronic Diseases and Metabolism, Leuven, Belgium;(3)Mount Sinai Kravis Children@E@s Hospital- Icahn School of Medicine Mount Sinai, Division of Pediatric Gastroenterology and Nutrition, New York, United States;(4)Landos Biopharma- Inc, Corporate Development, Blacksburg, United States;(5)Landos Biopharma- Inc, Clinical, Boston, United States;(6)IRCCS San Raffaele Scientific Institute- Vita-Salute San Raffaele University, Gastroenterology and Gastrointestinal Endoscopy Unit, Milan, Italy;(7)Cedars Sinai Medical Center, Division of Gastroenterology and Hepatology- Center for Inflammatory Bowel Diseases, Los Angeles, United States;
P740: Results at 52 weeks of Intravenous Ustekinumab as Maintenance Treatment in Patients with Loss of Response to Subcutaneous Doses: A Multicenter Retrospective Observational Study.ECCO'24Year: 2024
Authors: Valdés Delgado, T.(1);González Antuña, J.(1)*;Javier Rodriguez González, F.(2);Gutierrez Martinez, F.(2);Maldonado Pérez, B.(1);Castro Laria, L.(1);Belvis Jiménez, M.(1);Caunedo Álvarez, Á.(1);Alcain Martinez, G.(2);Camargo Camero, R.(2);Martos Van Dussen , J.V.(2);Fernández Castañer, A.(2);Argüelles-Arias, F.(1);
(1)Virgen Macarena University Hospital, Gastroenterology Department, Seville, Spain;(2)Virgen de la Victoria University Hospital, Gastroenterology Department, Malaga, Spain;
P741: Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s diseaseECCO'24Year: 2024
Authors: Reinisch, W.(1)*;Colombel, J.F.(2);Ma, C.(3);Long, M.(4);Irving, P.M.(5);O@E@Brien, D.(6);Kligys, K.(6);Song, A.(6);Zhang, Y.(6);D’Haens, G.(7);
(1)Medical University Vienna, Department of Gastroenterology and Hepatology, Vienna, Austria;(2)Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States;(3)University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Canada;(4)University of North Carolina, Center for Gastrointestinal Biology and Disease- Division of Gastroenterology and Hepatology, Chapel Hill, United States;(5)Guy@E@s and St Thomas@E@ NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(6)AbbVie Inc., Research and Development, North Chicago, United States;(7)Amsterdam University Medical Centers, Department of Gastroenterology, Amsterdam, The Netherlands;
P742: The efficacy of comprehensive multivitamin and mineral supplement to treat symptoms of fatigue in patients with Inflammatory Bowel Disease in remission with immunomodulators and or biological agents.ECCO'24Year: 2024
Authors: Laheij, R.(1)*;Bierens-Peters, D.(1);Bruin, K.(1);Lutgens, M.(1);Sikkema, M.(1);de Wit, U.(1);Laheij, R.(1);
(1)Elisabeth-Tweesteden Hospital, Department of Gastroenterology and Hepatology, Tilburg, The Netherlands;
P743: A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitisECCO'24Year: 2024
Authors: Croft, A.(1,2,3)*;Okano, S.(4);Hartel, G.(4);Lord, A.(3);Walker, G.(1,2,3);Radford-Smith, G.(1,2,3);
(1)Royal Brisbane and Women@E@s Hospital, Department of Gastroenterology and Hepatology, Brisbane, Australia;(2)University of Queensland, Faculty of Medicine, Brisbane, Australia;(3)QIMR-Berghofer MRI, Gut Health Group, Brisbane, Australia;(4)QIMR-Berghofer MRI, Biostatistics, Brisbane, Australia;
P744: Evaluation of a lifestyle program based on physical activity on quality of life and fatigue in patients with Inflammatory Bowel Disease: a pilot studyECCO'24Year: 2024
Authors: Van De Pol, N.(1)*;Visser, E.H.(2);van der Woude, C.J.(1);de Vries, A.C.(1);de Jonge, V.(3);West, R.L.(2);
(1)Erasmus University Medical Center, Gastroenterology and hepatology, Rotterdam, The Netherlands;(2)Franciscus Gasthuis & Vlietland, Gastroenterology and hepatology, Rotterdam, The Netherlands;(3)Albert Schweitzer Hospital, Gastroenterology and hepatology, Dordrecht, The Netherlands;
P745: Assessment of Crohn’s disease patients following risankizumab initiation using intestinal ultrasound: A prospective studyECCO'24Year: 2024
Authors: Rosentreter , R.(1);Ingram , R.(1);Ma , C.(1);Chan , M.(1);Shukla , T.(1);Devlin , S.(1);Kaplan , G.(1);Seow , C.(1);Panaccione , R.(1);Novak , K.(1);Lu , C.(1)*;
(1)University of Calgary, Division or Gastroenterology and Hepatology- Department of Medicine, Calgary, Canada;
